Personalis NeXT Disease Test Approved for Expanded Coverage by Medicare, Medicaid
20 maj, 12:31
06:31 AM EDT, 05/20/2026 (MT Newswires) -- Personalis (PSNL) said Wednesday its NeXT personal minimal residual disease test has been approved for expanded coverage by the US Centers for Medicare &Medicaid Services'Molecular Diagnostic Services Program.
The approval is for monitoring treatment response to neoadjuvant therapy in patients diagnosed with Stage II-III triple-negative breast cancer or HER2-positive breast cancer, it said Wednesday.
The coverage decision was backed by clinical evidence from a 227-patient study showing monitoring with NeXT allows accurate tracking of therapy response, outperforming standard clinical metrics, the company said.
Ämnen i artikeln
Personalis NeXT Disease Test Approved for Expanded Coverage by Medicare, Medicaid
20 maj, 12:31
06:31 AM EDT, 05/20/2026 (MT Newswires) -- Personalis (PSNL) said Wednesday its NeXT personal minimal residual disease test has been approved for expanded coverage by the US Centers for Medicare &Medicaid Services'Molecular Diagnostic Services Program.
The approval is for monitoring treatment response to neoadjuvant therapy in patients diagnosed with Stage II-III triple-negative breast cancer or HER2-positive breast cancer, it said Wednesday.
The coverage decision was backed by clinical evidence from a 227-patient study showing monitoring with NeXT allows accurate tracking of therapy response, outperforming standard clinical metrics, the company said.
Ämnen i artikeln
Styrräntan
Styrräntan
Marknadsöversikt
1 DAG %
Senast
1 mån
